Phase II evaluation of vindesine in mycosis fungoides, extraosseous plasmacytoma and other hematologic malignancies

E. Ferrazzi, G. L. Pappagallo, R. Segati, O. Vinante, E. Galligioni, V. Zagonel, L. Salvagno, M. V. Fiorentino

Research output: Contribution to journalArticle

Abstract

The authors conducted a phase II trial of vindesine in 24 patients, mostly pretreated (23/24 fully evaluable for therapeutic response) with advanced hematologic malignancies. The drug was administered at weekly bolus doses of 3 mg/m 2 i.v. Overall, objective tumor regressions were seen in 9 of 23 patients. The drug appeared effective in extraosseous plasmacytoma (1 complete response and 1 minor response in 3 patients) and in mycosis fungoides (1 complete response, 1 partial response and 1 minor response in 6 patients). Further phase II trials in these 2 diseases are justified. In addition, 3 partial responses in 7 patients with advanced lymphoma were also obtained. Previous vinca-alkaloid exposure did not adversely affect the response rate: 8 of 9 responsive patients had previously received vincristine and/or vinblastine. Drug-related toxic effects were mainly represented by manageable and reversible neurotoxicity and by moderate leukopenia with apparent lack of thrombocytopenia. In heavily pretreated patients, leukopenia may be occasionally severe: in these conditions a starting dose of 2 mg/m 2 seems more appropriate.

Original languageEnglish
Pages (from-to)321-324
Number of pages4
JournalTumori
Volume68
Issue number4
Publication statusPublished - 1982

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research

Cite this

Ferrazzi, E., Pappagallo, G. L., Segati, R., Vinante, O., Galligioni, E., Zagonel, V., Salvagno, L., & Fiorentino, M. V. (1982). Phase II evaluation of vindesine in mycosis fungoides, extraosseous plasmacytoma and other hematologic malignancies. Tumori, 68(4), 321-324.